Sinobiomed’s current growth strategy focuses on innovative recombinant protein biopharmaceutical drug discovery, development, manufacture and distribution. We focus on targeted high potential therapy areas to serve clinical needs that are unmet or underserved by current products. Sinobiomed also actively seeks acquisitions that enhance or expand product development and/or marketing and would be accretive to shareholder value.

In executing this strategy, the Company leverages current assets that include:

• extensive intellectual capital, research and development resources
• strong university and research centre alliances, both domestic and international
• highly skilled proven drug discovery and development talent pool
• established integrated research and manufacturing facilities that meet GMP
• patented low-cost, high yield production process
• strong government and international agency support through funding and co-development agreements